Qiagen N.v. · NYSE:QGEN
Qiagen — Q2 2025 Earnings Presentation
23 slides from Qiagen's earnings presentation, Aug 6, 2025
Slide 1: Q2 2025 results
Q2 2025 results Solid performance exceeding outlook August 5, 2025
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 3: Q2 2025: Solid performance exceeding outlook
Q2 2025: Solid performance exceeding outlook Growth Solid performance with continued strength across the portfolio $534 mn ($526 mn CER) • Net sales +6% CER to $534 mn ahead of outlook for ~+5%; core sales +6% CER Net sales • QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER) lead pillars, while autom
Slide 4: Q2 2025: Sales performance and key developments
Q2 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +6% Sample • Steady CER sales as automated kits offset soft manual kits CER(1) technologies • Instrument placements led by QIAsymphony and EZ2 systems 496 534 Sample • +11% CER gro
Slide 5: Q2 2025: Portfolio developments
Q2 2025: Portfolio developments Sample technologies: QIAcuity: QIAGEN Digital Insights: Advancing automated sample preparation Advancing cell therapy analytics Advancing genomic insights for clinicians Three new instruments progressing Expanded dPCR portfolio for lentiviral Genoox adds Franklin clou
Slide 6: Q2 2025: Ongoing solid profitability improvements
Q2 2025: Ongoing solid profitability improvements Adj. operating income margin Adj. EPS ahead of Q2 2025 outlook Adj. +13% to $160 million on efficiency operating gains and NeuMoDx discontinuation +1.5 ppt 29.9% income 28.4% Non- operating 20% adj. tax rate above ~19% target income $0.60 Adj. EPS(1)
Slide 7: H1 2025: Continuous high cash flow
H1 2025: Continuous high cash flow Cash flow(1) Debt maturity overview(3) (in $ millions) In $ millions Q2 2025 Q2 2024 Change Operating cash flow 161 167 -3% 624 Purchases of PP&E(2) -40 -38 +5% 124 500 Likely Free cash flow 121 129 -6% repayment in 2025(4) 500 164 60 82 In $ millions H1 2025 H1 20
Slide 8: Disciplined capital allocation to create value
Disciplined capital allocation to create value Profitable targeted investments Annual dividend Organic payment investments Into growth pillars and digitization to fuel profitable business expansion First-ever dividend totaling $54 mn paid in July 2025 after AGM approval Focused Value-creating transa
Slide 9: Outlook: Q3 and FY 2025
Outlook: Q3 and FY 2025 As of August 1, 2025 Outlook Q3 2025 FY 2025 Net sales ≥+4% CER / +4-5% CER(2) / ≥+5% CER core portfolio(1) +5-6% CER core portfolio(1,3) Anticipated currency impact Positive impact of <+1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS ≥$0.58 CER ~$2.35 CER Anticipated c
Slide 10: Appendix
QIAGEN Appendix
Slide 11: Q2 and FY 2025: Outlook and assumptions
Q2 and FY 2025: Outlook and assumptions (As of August 1, 2025) Q3 2025 outlook FY 2025 outlook Net sales ≥+4% CER / ≥+5% CER core portfolio(1) +4-5% CER / +5-6% CER core portfolio(1) (Previously ~+4% CER / ~+5% CER core portfolio) Anticipated currency impact(2) Positive impact of <+1 ppt Positive im
Slide 12: Q2 2025: Consolidated Statements of Income (unaudited)
Q2 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended June 30, 2025 June 30, 2024 Net sales 533,540 496,347 Cost of sales: Cost of sales 185,951 446,371 Acquisition-related intangible amortization 13,303 15,212 Total cost of
Slide 13: H1 2025: Consolidated Statements of Income (unaudited)
H1 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Six months ended Six months ended June 30, 2025 June 30, 2024 Net sales 1,016,996 955,143 Cost of sales: Cost of sales 347,245 598,105 Acquisition-related intangible amortization 26,784 31,285 Total cost of sa
Slide 14: 2025: Quarterly sales by product group
2025: Quarterly sales by product group Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% 166 2% 0% 316 -1% -1% Diagnostic solutions(1) 187 9%
Slide 15: 2025: Quarterly sales by product type and region
2025: Quarterly sales by product type and region Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 435 6% 8% 476 8% 6% 911 7% 7% revenue
Slide 16: Q2 and H1 2025: Reconciliation to adjusted results (unaudited)
Q2 and H1 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Second quarter 2025 Reported results 533.5 334.3 121.9 126.8 (30.6) 24 % 96.2 0.44 Adjustments Business integr
Slide 17: Q2 and H1 2025: Footnotes for reconciliation to adjusted results
Q2 and H1 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Results include costs for acquisition projects, including the acquisition of GNX Data Systems Ltd. (doing business as Genoox) completed in May 2025. It also includes costs incurred in connection with streamlining operati
Slide 18: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 533.5 1,017.0 Net sales (CER) 491.2 525.8 1,016.9 Gross profit 308.7 334.3 643.0 Gross profit margin 63.8% 62.7% 63.2% Adjusted gross profit
Slide 19: Consolidated Balance Sheets (unaudited)
Consolidated Balance Sheets (unaudited) December 31, December 31, (In $ thousands, except par value) June 30, 2025 2024 (In $ thousands, except par value) June 30, 2025 2024 (revised) (revised) Assets Liabilities and Equity Cash and cash equivalents 733,815 663,555 Current portion of long-term debt
Slide 20: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Six months ended Six months ended (In $ thousands) June 30, 2025 June 30, 2024 (In $ thousands) June 30, 2025 June 30, 2024 Cash flows from operating activities: Cash flows from financing activities: Net income (loss) 187,008 (102,787) Capital repaym
Slide 21: Q2 and H1 2025: Currency impact
Q2 and H1 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q2 2025 U.S. dollar 295.8 295.9 56% 0.1 Euro 112.5 106.6 20% -5.9 British pound 17.5 16.6 3% -0.9 Japanese yen 9.2 8.5 2% -0.7 Other currencies 98.6 98.2 19
Slide 22: Employees as of June 30, 2025
Employees as of June 30, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q2 2025 Q1 2025 Change Production 300 1,123 147 1,570 1,728 -9% R&D 165 773 55 993 847 17% Sales 549 840 715 2,104 2,101 0% Marketing 68 177 74 319 327 -2% Administration 79 444 153 676 670 1%
Slide 23: Your contacts
Your contacts Dr. Domenica Martorana Calendar Associate Director E-mail: Global Investor Relations Q3 2025 results November 2025 ir@qiagen.com Phone: +49 2103 29 11244 Internet: Q4 2025 results February 2026 E-mail: domenica.martorana@qiagen.com corporate.QIAGEN.com Alexandra Koenig Share informatio